Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma

Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free survival in the adjuvant therapy setting (CHECKMATE...

Descripción completa

Detalles Bibliográficos
Autores principales: Högner, Anica, Thuss-Patience, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918118/
https://www.ncbi.nlm.nih.gov/pubmed/33673374
http://dx.doi.org/10.3390/ph14020151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918118/
https://www.ncbi.nlm.nih.gov/pubmed/33673374
http://dx.doi.org/10.3390/ph14020151

Ejemplares similares